To quantify concentrations of anti-growth hormone antibody in >600 serum samples by radioimmunoassay, we devised a system ("B0LAc") to process data and to execute the curvefitting program LIGAND-PC automatically with an IBM PCcompatible computer. We fit data from each sample to four binding models comprising different combinations of nonspecific binding and one-or two-antibody binding sites. Total antibody concentration is then calculated from the model that is statisticaHy "best." This process occasionally selects a two-binding-site model that severely overestimates the antibody concentration. Errors of this kind are discarded by constraining the product of the second-site antibody's affinity and its concentration to exceed a minimum value (0.05). We evaluated the performance of the B0L.Acsystem by assaying controls and by using computer simulations to demonstrate the high confidence levels attainable in estimation of antibody concentrations. Between-assay variability (CV) was <25%, and analytical recovery exceeded 90%. In many cases, a quantitative increase in incidence and level of antibody responses attending the substitution of a modified product for the natural one will weigh heavily against acceptance of the former. There is thus a need to accurately quantify specific antibodies in a manner that allows unequivocal comparisons of immunogenicity.
In many cases, a quantitative increase in incidence and level of antibody responses attending the substitution of a modified product for the natural one will weigh heavily against acceptance of the former. There is thus a need to accurately quantify specific antibodies in a manner that allows unequivocal comparisons of immunogenicity.
In the past, when precisely defined concentrations of specific antigens and antibodies were usually not available, antibody responses were generally determined only in relative terms. In keeping with standard practices in the biological sciences, therefore, antibody responses were reported in units, titers, or degrees of response. Now that purified hormones and peptides are being produced by recombinant DNA technology, it has become much easier to determine antibody responses in quantitative terms, e.g., thermodynamic affinity and concentration. During clinical evaluation of human growth hormone (hGH), we developed methods to estimate quantitatively the level of antibody responses to hGH in serum from patients treated with growth hormone.' At tissue in particular was whether hGH without an N-terminal methionine ("authentic" hGH, somatotropin) was less immunegenic than methionyl hGH (met-hGH, somatrem). Initial studies demonstrated that the incidence of antibody responses was considerably higher in patients being treated with met-hGH (8-14). It became necessary to quantify these responses, given the body of literature on experience with pituitary-derived hGH, which showed that resistance to hGH therapy is correlated with the quantitative concentration, or binding capacity, of hGH-specific antibodies (2, 3) .
The measurement of antibodies, receptors, or other binding proteins in absolute units of concentration requires the use of competitive binding assays, with computerized fitting of the data by nonlinear least squares (NLLS) or similar approaches (15) (16) (17) . The assay is standardized with accurately determined concentrations of unlabeled ligand; no calibration with arbitrary antibody or receptor standards is necessary.
An examination of the literature regarding use of curve fitting to estimate concentrations of antibodies in serum reveals that such curve fitting usually has been done either by graphical analysis or by methods of computation that would prohibit interlaboratory comparison (3, 7,15,18,19) .
With the popularization of software for such curve fitting, it is now possible to remove subjectivity from the process of fitting competition immunoassay data. Here we describe computer methods by which the "LIGAND" curve-fitting program can be run in a batch mode, thereby bringing the benefits of NLLS treatment of data to the routine analysis of large numbers of samples.
What remains, however, is the need to determine the limits of reliability within which fitted estimates can be accepted. Most immune responses are polyclonal in nature, with high-and low-affinity responses contributing in various degrees. To determine total antibody concentration accurately, therefore, one frequently must fit the data by report only high-affinity results, obtained at high dilution (16, 20) .
Here we describe experimental, computational, and theoretical methods to optimize the discrimination of lowaffinity sites from nonspecific ones, while preserving the utility of a routine method for precise quantification of antibodies specific for a given antigen.
Materials and Methods

Materials
Samples: Serum samples were obtained from patients enrolled in clinical trials of recombinant human growth hormone (somatrem and somatropin) (14) . Some patients had previously undergone therapy with pituitary-derived growth hormone, while others were naive to treatment.
Antibodies: Guinea pig and rabbit antisera to hGH were prepared by immunization techniques as previously described (21) . The sera were taken 10 days after the third monthly booster injection. Two monoclonal antibodies to hGH were obtained from Hybritech, Inc., La Jolla, CA:
products number GHCO72 and GHC1O1, human growth hormone was produced at Lilly and was greater than 99% monomeric hGH by size-exclusion HPLC (22) . Labeled hGH ('251-labeled hGH) was prepared by the lactoperoxidase (EC 1.11.1.7) method and purified by chromatography on Sephadex G-75 to remove possible interferences due to aggregates and lactoperoxidase (23). The '251-labeled hGH had a specific activity of 30 to 50 CiJg and was used within three weeks of preparation.
Methods
Serum binding test: For routine determination
of antibody responses to hGH, samples were first screened by a serum binding test (SBT). In this test, serum samples were analyzed at a final dilution of 50-fold in 0.5 mL of pH 8.8 assay buffer (per liter: 10 mmol of Tris, 140 mmol of NaC1, 25 mmol of EDTA, and 10 g of bovine serum albumin) containing 150 pg of lsl.labeled hGH (approx. 12000 disintegrations/min). After incubation overnight at 25#{176}C, the bound '251-labeled hGH was precipitated by addition of 0.1 mL of a 5 g/L solution of bovine gamma globulin and 0.6 mL of a 250 g/L solution of polyethylene glycol 8000 (24) . For some studies, samples were incubated for three days at 4#{176}C. The percentage of 125I-labeled hGH bound (%B) was calculated as [(S -BL)/(T -BL)] x 100, where S is the average sample counts per minute, T is the average total counts per minute originally added, and BL is the average blank counts per minute in the presence of buffer alone. Samples with a %B greater than twice the mean response of a panel of 12 normal sera were considered potentially positive for hGH antibodies.
Samples potentially positive for hGH antibodies by the SBT were further screened for inhibitable binding by repeating the SBT with an additional set of tubes containing 10 pg of hGH. Any sample whose %B upon inhibition dropped to less than half of its value when uninhibited was then further analyzed with a capacity assay. In addition, all samples with %B >20 were analyzed in the capacity assay regardless of their response to inhibition. (Figure 1) , so that multiple samples could be processed completely unattended. This operation of LIGAND in a batch mode was given the acronym BOLAC (for Batch Operation of LIGAND for Antibody Capacity). BOLAC also included programs top the output from LIGAND into results files and to calculate the antibody binding capacity from the "best" fit for each sample, as discussed below.
Curve-fitting procedure: The LIGAND program uses a weighted nonlinear least squares approach to fit competitive assay data to an equilibrium model allowing for multiple binding sites (16). For our studies, the equation describing the model can be written as
This equation expresses the familiar Scatchard ratio of bound ligand to free ligand (B/F) as a sum of terms representing specific binding (the first two terms) and nonspecific binding (N). The first two terms express specifically bound ligand as functions of K1, and K12, the affinity constants for the first (higher affinity) and second (lower affinity) antibody populations, with concentrations R1 and R2, respectively.
The second term of Equation 1 is omitted when a model is considered involving
only one antibody
population.
We used the BOLAC system to fit the data from each sample to four variations of the binding model. These are listed in Table 1 . The value to use for N as a constant was determined by running a normal serum control in each day's assay. This set of control data was fitted by the LIGAND program, with N used as the only fitted parameter.
In selecting the best model to use for calculating antibody concentration in a given sample, our first criterion was that the significance parameter P be <0.05, i.e., that there be greater than 95% confidence that the model under consideration was more appropriate than a simpler one (25). We further set an upper limit of acceptability for the coefficient of variation of the calculated capacity values of 150%. If either of these criteria were not met, then the next-best fit would be considered. Results were converted to units of milligrams of hGH binding capacity per liter of serum by multiplying the value of R, (or the sum R, + R2 for a two-site model) by a constant, 5.5 x ion,based on a molecular mass of 22 000 Da for hGH and a factor of 250 for final dilution. Computer simulations: We wrote a program (sIMFrr) that accepted values for K's, R's, and N and, using Equation 1, calculated the expected bound ligand concentrations for each of the 10 total ligand concentrations we use in our capacity assay. The error structure of our data could also be incorporated into the simulated data (27, 28) . SIMFIT arranged the data in a format required by LIGAND. BOLAC then fitted the simulated data in the same manner used for actual data.
Results
We optimized conditions of pH, ionic strength, and incubation time and temperature for the determination of hGH antibodies. Pooled specimens of positive human serum and controls made of immune animal sera diluted in normal human serum were analyzed in the serum binding test, to evaluate specific binding. We analyzed normal human sera to evaluate nonspecific binding. It was found that specific binding was fairly immune to changes in a variety of conditions. For example, positive controls showed less than 10% change in the %B values over the temperature range 4 to 37#{176}C. Likewise, varying either the pH (from 6.5 to 9.0) or the incubation time (from 18 h to 78 h) had relatively little effect on %B responses. However, each condition had a significant impact on the blank binding and on binding by normal serum. Because these two values largely determine the sensitivity of the assay, it was important to minimize them. The selection of the pH 8.8 assay buffer described above, together with overnight incubation at 21 #{176}C, caused blank and normal serum binding levels to drop considerably (6% and 2.3%, respectively). When the assay was run in a similar buffer, but using 0.01 molfL phosphate at pH 7.4 with 72 h of incubation at 4#{176}C, the binding by normal serum was nearly threefold higher.
We used results from repeated analyses of positive control samples to estimate the precision of the serum binding test. These controls were composed of guinea pig or rabbit antisera to hGH diluted in normal human serum. Table 2 shows that for controls with significant binding (B, C, G, and H) the interassay coefficient of variation (CV) was generally <7%, whereas for less-positive controls the CV for the %B values was higher, because these values are near the assay background. However, the reproducibility of detecting these controls as positive or negative was quite good. The D, I, and J controls were consistently positive, whereas the B control was always negative.
We validated the use of polyethylene glycol precipitation Table 4 , the CVs of all concentration estimates were <50%. Discrimination of second sites from nonspecific binding: About 10% of samples fell into a category in which Model 3 fit the data statistically better than did the other models, and the second site had characteristically low affinity, high concentration, and high CV. These "marginal Model 3 fits" also had %B values in the SBT that were considerably lower than most samples with high capacities. It became apparent that in these cases the curve-fitting procedure was erroneously detecting a second population of antibodies. We sought to determine whether the marginal Model 3 fits could be distinguished from samples with genuine two-site binding on the basis of a relationship between K12
and R2. Figure 3A shows the correlation of the K12 and R2 values for all samples for which Model 3 best fit the data of the capacity assay. This plot illustrates that samples with high CVs for the R2 values (CV >50%) all fall within a region of the plot defined by K12. R2 <0.05 (i.e., to the left of the solid line in Figure 3, A or B) . Figure 3B 
Performance of the Capacity Assay2
Minimum reportable concentration:
During the validation of this assay, we observed that the CV that BOLAC assigned to binding capacity values increased dramatically at about 2 x 10-12 mol/L, or 0.01 mg of hGH binding capacity per liter. Figure 2 shows that, although some estimates of binding capacity below 0.01 mg/L are reasonably well-determined, over half have CVs >50%. The majority of capacities exceeding 0.01 mg/L have better precision. We chose to set a reporting limit at twice this value, or 0.02 mg/L.
Interassay precision: We estimated the precision of the hGH capacity assay from the performance of two controls, as described in Table 3 . For the control H (rabbit anti-hGH diluted 1:5000 in normal human serum), the interassay CV was 60% (n = 11), with a one-site fit consistently found. A one-site fit is expected, for although this control is made from a polyclonal antiserum, at sufficiently high dilution such high-titer antisera would be expected to exhibit homogeneous binding. The value of 60% reflects the precision typically seen for individual samples whose concentration is below the reporting limit of 0.02 mg/L.
The second control was a poo1 of positive human sera composed of samples shown to give two-site fits in the capacity assay. This pool thus allowed us to assess the precision of the assay for samples exhibiting two-site behavior. The interassay CV with which high-affinity binding 2 distinguish interassay CV from CV assigned by BOLACto a single result computedby NLLS curve fitting. In the latter case, CV is derived from the asymptotic variance-covariance matrix of the estimated parameters computedby NLLS. We use CV in this latter senseexceptwhere specificallyreferring to interassay CV. CV computed by NLLS should approximate interassay CV provided experimental design and error structure are invariant. Figure 4 shows that BOLAC can assign two-site (Model 3) fits to data generated by a simulation in which a single site of low concentration and high affinity is used. The low-affinity site contributes to a three-to 40-fold overestimate of the total binding capacity. The major factor leading to the detection of a nonexistent second site is a slight underestimation of the correct value for the nonspecific binding parameter N, as shown in Table 6 . These erroneous two-site fits had values of the product K12 . R <0.05 in all cases.
We also used simulations to validate the accuracy of BOLAC under a variety of conditions. We generated data sets for two-site systems with equal concentrations but differing affinities.
We observed that BOLAC correctly calculated total antibody concentrations (to within 33% of the actua.lvalue)foranydatasetinwhichR1 + R2 >2 X 10_12 mol/L and K11 > K12> 1 x iO Lfmol. However, when we used affinities less than 1 x iO L/mol, we observed that BOLAC occasionally estimated binding capacities incorrectly.
We then performed simulations of two-site models to evaluate the ability of BOLAC to find second sites as a function of the product of K12 and R2. In these simulations, a second population of antibodies was added to the singlesite simulation used in Figure 4 , with values for K12 ranging from 3 to 8 x iO L/mol and values of R2 adjusted to give the desired K12 . B2 product. We performed 10 simulations each for the case K12 . B2 = 0.05 and K12 . = 0.025. BOLAC correctly estimated the value of R2 (within a factor of 2) in nine of 10 simulations when the product K12 . B.2 was 0.05; the sole exception was close, within a factor of 2.5. In contrast, when K12 -112was 0.025, BOLAC was correct on only five of 10 tries. Four of these completely missed a second site, reporting antibody concentrations more than an order of magnitude too low.
Discussion
The quantitative assessment of antibody specific for a given antigen requires considerable amounts of informa- Forclarity, data points are omitted from two of the plots tion, analysis, and interpretation. This partly justifies the widespread use of semiquantitative variables such as per cent binding and titers, which require less experimental data. Techniques which involve antigen in a solid phase (e.g., ELISA, RAS'r, and IRMA) are widely used because of the speed and sensitivity with which antibodies can be detected. These techniques, while convenient, are inadequate for quantification of antibody in absolute units, because it is necessary to make assumptions about the detection reagents. For example, the enzyme activity of peroxidaseconjugated Protein A has been used to quantify bound IgG, assuming a 1:2 stoichiometry for the reaction of Protein A with IgG (29). When ELISA is used for absolute quantification of serum antibodies, the activity of a bound enzymelabeled anti-IgG has to be calibrated against some arbitrary standard. Some workers (30) have used a reference serum as a standard; others (31) have calibrated the enzyme activity by capturing IgG standards onto solid phases coated with anti-IgG instead of target antigen. Although these techniques can be made internally self-consistent, it is clear that, with them, results must be reported in method-related units, i.e., units that are meaningful only in the context of the specific method. Further, these techniques measure a mixture of affinity and concentration, not just concentration (19, 32-34) . Finally, solid-phase techniques give marked differences in reactivity, depending on the method used to immobilize the target antigen (35,36).
Bound liGH Concentration
Here we have presented a rational design for the routine screening and analysis of serum antibodies specific for a given compound. The serum-binding test selects only those samples that are potentially positive. The capacity assay then quantifies antigen-specific IgG in thermodynamic units of concentration and affinity. These elements of our approach are consistent with current practice but optimized with regard to speed and accuracy of data interpretation.
We have shown that the SBT screening is reliable and reproducible. We have set the SBT to give high sensitivity by optimizing assay conditions and by performing blank subtraction as described in the Methods section. These steps have established a threshold %B value for positives that is significantly lower than a threshold calculated without these steps.
1.0
Our results show that the BOLAC system accurately analyzes samples that are positive for hGH antibodies. BOLAC allows statistical comparisons of one -and two-site models for curve fitting of data, with each fit considering nonspecific binding as a fixed or fitted variable. This approach has been recommended if the LIGAND program is to be accurately used (16). We have undertaken to evaluate, through experimentation and computer simulation, the performance of BOLAC with respect to precision, sensitivity, and accuracy. In sodoing, we have established limits within which the assay produces accurate results for the specific antibody content of serum. We have shown that BOLAC detects hGH binding capacity down to 0.02 mg/L. The incremental increase in error with decreasing concentration was shown experimentally and by simulation to increase considerably at this detection limit. A lower detection limit would be practically achievable only by using 1251labeled hGH of higher specific activity, and only if the antibodies to be measured had affinities >1010 L/mol BOLAC's detection limit is already >100-fold lower than values considered to be clinically significant (2). We assessed the accuracy of the BOLAC system by its ability to quantify known amounts of monoclonal anti-hGH antibodies added to normal human serum. Results of our simulations showed that BOLAC accurately measures antibody concentrations across a wide range of antibody affinities. BOLAC displays a degree of reproducibility that is quite acceptable for an assay based on curve fitting. A CV of 25% for estimates of antibody concentration, although higher than that expected of most clinical assays, is nonetheless sufficient to detect clinically significant changes in antibody status, with the advantage of reporting results in unambiguous units. This approach has been successfully applied to clinical studies of hGH therapy involving over 10000 serum samples. Approximately 600 samples in these studies passed the screening test and have had to be analyzed by the capacity assay.
The four-model approach used in BOLAC was adopted to obtain as much statistically valid information as possible from the data of the capacity assay. Our choice of 10 ligand calibrators spanning three orders of magnitude of concentration was dictated by the need to quantify antibody over a wide dynamic range. Increasing the number of ligand concentrations could improve the ability to resolve multiple-site binding (37) but would not improve the ability to measure total antibody concentration. BOLAC occasionally assigned high capacity to samples with suspiciously low binding in the SBT. This invariably resulted from selection of Model 3 as the best fit, with relatively low affinities (less than iO L/mol) for the second site. Affinity K and capacity H are inversely correlated, so these low-affinity sites would calculate out to quite high concentrations. In these cases, clearly nonspecific binding has been misinterpreted as low-affinity binding. 16,38) . However, the recourse to changes in experimental conditions or pooling of multiple data sets recommended by these authors is not practical for the routine analysis of antibody in patients' samples. We suggest that the product of K12 and R2 be required to exceed 0.05 before a two-site fit for measurement of serum antibody is accepted. Such a criterion allows nonspecific binding to be best estimated, in effect, either by the analyst or by the program, with little danger of overestimating antibody concentrations. In the BOLAC system, Model 2 or 3 is selected most frequently, because when a one-site model is sufficient, usually N is fairly well defined by the data, whereas for two-site fits N is often not as well defined by the data and therefore is better left fixed at predetermined values. Burgisser (39) has demonstrated that experimental error plays a major role in causing misinterpretation of radioligand binding data. Our modeling studies suggest that, in a clinical setting involving high throughput, the treatment of nonspecific binding becomes a more important source of potential error.
Munson
It can be argued that the 0.05 criterion arbitrarily rejects low-affinity antibodies. For example, an antibody of affinity 5 X iO Limo! would have to be present at the rather high concentration of 1 x iO-mol/L (IgG 40 ug/mL in the original serum) to be reported. It is certainly possible that such low-affinity antibodies exist in serum, but at the concentrations below which the 0.05 criterion rejects them, they would be expected to contribute negligibly to the binding of hormones that circulate in concentrations <1 nmol/L-as do, for example, hGH and insulin. Thus the 0.05 criterion places the capacity assay into a region of clinical relevance. If sufficient sample is available, then performing the capacity assay at a dilution less than 50-fold could increase the sensitivity with which lowaffinity antibodies can be detected. The 0.05 criterion should still apply, however.
The automation of data acquisition and processing described here makes it possible to estimate antibody concentration accurately in absolute units. Integration of these features into a flexible system such as BOLAC provides the basis for bringing quantification of antibody into the realm of modern analytical practice, unencumbered by the artifacts or methodological limitations that, in other techniques, result in only relative results being reported.
